Welcome and introduction
Maintenance/consolidation therapy for advanced NSCLC: Are there new standards of care?
Can clinical markers, histology and molecular markers guide our management strategies for NSCLC: What do recent clinical trial results demonstrate?
Targeting EGFR and VEGF/VEGFR in NSCLC: Choosing the best targeted agents to combine with chemotherapy using clinical and biologic prognostic factors
Emerging targets and therapeutic agents for NSCLC: m-TOR inhibitors, c-met inhibitors, IGF1R inhibitors, HSP90 inhibitors, Src inhibitors and others
- 2009-10-27 00:00:00 2009-10-27 23:59:59 Europe/Prague Emerging Therapies for Lung Cancer Morton’s The Steakhouse, Miami, Florida, USA